Skye Bioscience, Inc.
SKYESkye Bioscience, Inc.
NASDAQ
Healthcare
Biotechnology
$0.66
-0.01(-1.32%)
52W $0.58 – $4.75
AI-generated
Skye Bioscience, Inc.
$22MMkt Cap
—Rev TTM
-$45MNI TTM
-0.5xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 9, 2026Skye Bioscience, Inc. reported a net loss of $55.9 million for fiscal year 2025, driven by significant operating expenses totaling $58.2 million, which resulted in an operating loss of $58.2 million. The company's research and development expenses were $42.4 million, while general and administrative expenses were $15.8 million. Total assets stood at $28.3 million, with current assets of $27.1 million...
What Changed Recently
Fundamentals
How The Business Makes Money
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Industry Biotechnology
Analyst View
Company Profile
CIK0001516551
ISINUS83086J2006
CUSIP83086J101
Phone858 410 0266
Address11250 El Camino Real, San Diego, CA, 92130, US
SEC EDGAR